Loading quotes...
Forecast
| Buy |
1 |
| Hold |
2 |
| Sell |
0 |
Discussions in the community
Translated from German
Roast my Portfolio – My Path to Financial Freedom 📈Hey everyone! 👋 I'm 27 years old and have been investing in stocks since early 2024. My goal is to build a dividend portfolio over the long term that will eventually enable me to achieve financial…
Nekromannte IV in Portfolio Roasts 9 28Translated from German
Display of time even though it was not recordedGood evening, I just happened to notice that manually recorded distributions show a time even though no time was recorded. Is this intentional or a bug? Regards
p phil III in Schnack
1 5Translated from German
Roast my portfolio 👀Dear Parqet Community, here's my portfolio consisting of about 70 individual stocks! I (m, 30, entrepreneur (retail and real estate) from Vienna) have been active in the stock market since 2017, but…
u user_e3b3a9 III in Portfolio Roasts
11 15Translated from German
Would love your thoughts on this (;Hey, I'm DividendCow, 22 years old and have been investing with ING since January. My current portfolio looks like this: https://app.parqet.com/p/67a3c751de0c6dc54e8dd1e7 My stocks are for my tax…
DividendCow IV in Portfolio Roasts 2 21Translated from German
How high is your annual dividend? If you like surveys as community comparisons, give it a like and I'll post them more often.Survey: Annual Gross Dividend under 2,000€ 2,000€ to 4,000€ 4,000€ to 6,000€ 6,000€ to 9,000€ over 9,000€
Marcus I in Schnack 37 14
News Go to news feed
Bayer rises sharply, but Monsanto legacy burdens hold back return to record high
Bayer has more than doubled over the past twelve months and has nearly tripled since the start of 2025, but remains well below the 2015 record high of €145.80. The recovery is driven by approvals such as the stroke drug Asundexian, strong sales from products like Nubeqa, and upward revisions to annual targets after a net profit of €5.2 billion in nine months. At the same time, settlements in the Monsanto glyphosate litigation (Bayer has set aside $7.25 billion) and cost savings from 12,000 job cuts could reduce the risk. Sixteen of 21 analysts recommend the stock; the expected P/E ratio is 19, below the sector average of 23. » More on handelsblatt.com
Bayer raises annual targets after approval of stroke drug Asundexian
Bayer saw its share price rise by more than 100 percent last year, but remains far below the all-time high before the Monsanto takeover. US approval for the stroke drug Asundexian and strong sales of new medicines such as Nubeqa and Kerendia are driving growth, prompting the group to raise its annual targets. Pressure from the wave of Monsanto lawsuits is easing after a ruling reduced many plaintiffs' chances of success and Bayer set aside $7.25 billion for out-of-court settlements. CEO Bill Anderson is focusing on cost cuts and simplified structures; analysts mostly rate the stock as buy and see the price-earnings ratio of around 19 as still attractive compared with the sector. » More on handelsblatt.com
Bayer receives approval for Asundexian in China and the US – Germany must wait
Bayer has received approvals for the new stroke drug Asundexian in China and the US. Approval in Germany is still pending, so patients there will have to wait. The development reflects the growing practice of introducing new drugs first in foreign markets. » More on wiwo.de
Bayer: stroke drug Asundexian approved in USA and China, Europe still pending
Bayer has received approvals for the Wuppertal-developed active ingredient Asundexian (brand name Sunharbo) in China and the USA; a European and German approval is being sought for next year. In a study, the drug reduced the risk of a recurrent ischemic stroke by 26 percent in over 12,000 patients. Analysts estimate peak annual sales potential of up to two billion euros in Europe and the USA; Bayer gives no official figures and initial sales expectations had been significantly higher. The group is simultaneously investing in a new plant in the USA while the market launch in Europe remains delayed. » More on wiwo.de
Bayer beats Q3 expectations thanks to pharma growth, analysts react differently
Bayer reported a better-than-expected third quarter, driven by its pharmaceuticals division and products such as Nubeqa. Goldman and UBS raised their price target to €66.00 and recommend “Buy,” while Jefferies remains at “Hold” with a €46.00 target and points to possible one-off items. Adjusted EBITDA surprised on the upside, but core earnings per share stayed below consensus. Investors are cautious after the strong share-price rise, as parts of the success could be deemed unsustainable. » More on deraktionaer.de
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 10.05B | 4.07% |
| Gross profit | 5.45B | 1.85% |
| Net profit | -672M | 30.22% |
| EBITDA | 1.53B | 151.65% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €56.14B |
Number of shares | 982.42M |
52-week high/low | €57.84 - €26.64 |
Dividend yield | 0.19% |
Dividends TTM | €0.11 |
Beta | 0.81 |
P/E ratio | -38.87 |
PEG ratio | 0.01 |
P/B ratio | 1.92 |
P/S ratio | 1.23 |
Company profile
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
| Name | Bayer |
| CEO | Bill Anderson |
| Headquarters | Leverkusen,
nw Germany |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 12/16/1996 |
| Employees | 87,775 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | BAYZF |
XETRA | BAYN.DE |
Stuttgart | BAYN.SG |
München | BAYN.MU |
Frankfurt | BAYN.F |
Berlin | BAYN.BE |
Düsseldorf | BAYN.DU |
Hamburg | BAYN.HM |
London | 0P6S.L |
SIX | BAYN.SW |
Wien | BAYN.VI |
Milan | 1BAYN.MI |
Warschau | BAY.WA |
Wse | BAY.WA |